INTERNATIONAL PATENT: ASTRAZENECA AB, SILENCE THERAPEUTICS GMBH FILES APPLICATION FOR "DOUBLE-STRANDED RNAI AGENTS AND COMPOSITIONS FOR REDUCING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3) AND METHODS OF USE THEREOF"

GENEVA, Aug. 18 -- ASTRAZENECA AB (SE-151-85 Sodertalje), SILENCE THERAPEUTICS GMBH (Robert-Rossle-Strasse 1013125 Berlin) filed a patent application (PCT/IB2025/051304) for "DOUBLE-STRANDED RNAI AGENTS AND COMPOSITIONS FOR REDUCING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3) AND METHODS OF USE THEREOF" on Feb 07, 2025. With publication no. WO/2025/169133, the details related to the patent application was published on Aug 14, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): FOINQUINOS, Ariana (c/o AstraZeneca ABSE-151 85 Sodertalje), HURT-CAMEJO, Eva (c/o AstraZeneca ABSE-151 85 Sodertalje), ...